Podcast Episodes
Back to Search
Mar 25, 2026 | Merck's $6.7B Terns Acquisition for CML Drug TERN-701
Merck pays $6.7B for Terns Pharmaceuticals and its CMLcandidate TERN-701 as the Keytruda patent cliff nears. FDA approves Denali's Avlayah — the firs…
5 months, 3 weeks ago
Mar 24, 2026 | ImmunityBio's Third FDA Warning Letter; Gilead Bets $1.68B on Ouro Medicines Autoimmune Bispecifi...
ImmunityBio stock crashes 21%+ after FDA names CEO andchairman in third ANKTIVA promotional warning letter in seven months. Gilead acquires Ouro Medi…
5 months, 3 weeks ago
Mar 23, 2026 | Apogee Eczema Data Sends Stock Up 20%; Gilead Nears $2B Ouro Medicines Deal
Apogee's zumilokibart shows every-3-to-6-month dosing in atopic dermatitis, stock surges 20%+. Gilead nears $2B Ouro Medicines acquisition. Insmed Ar…
5 months, 3 weeks ago
Mar 22, 2026 | Abbott's $21B Exact Sciences Deal Closes; Wegovy HD Approved, Orforglipron Delayed
Abbott finalizes its ~$21B Exact Sciences acquisitionMonday, reshaping cancer diagnostics. Novo's Wegovy HD wins FDA approval as Lilly's orforglipron…
5 months, 3 weeks ago
Mar 20, 2026 | Novartis $2B Bet on PI3Kα in Breast Cancer; Opdivo Approved for Hodgkin Lymphoma
Novartis pays $2B upfront for Synnovation's Phase 1/2 PI3Kα inhibitor SNV4818 to defend its HR+/HER2- breast cancer franchise. Plus: BMS Opdivo wins …
5 months, 4 weeks ago
Mar 19, 2026 | Lilly Retatrutide Phase 3 Clears All Endpoints; FDA Approves Wegovy HD in 54 Days
Retatrutide delivers 2.0% A1C reduction and 16.8% weightloss in 537 T2D patients — Lilly's triple agonist clears its first Phase 3 hurdle the same da…
5 months, 4 weeks ago
Mar 18, 2026 | FDA Approves J&J's Oral Psoriasis Pill Icotyde; Bicycle Therapeutics Cuts 30% of Workforce
FDA approves J&J's Icotyde — the first oral IL-23Rpeptide for psoriasis — with $5B+ peak sales projected. Plus Bicycle Therapeutics shelves lead canc…
6 months ago
Mar 17, 2026 | Aldeyra's Third FDA Rejection Crashes Stock 68%; CytomX Masked ADC Surges 60%
Aldeyra Therapeutics crashes ~68% after the FDA rejectsreproxalap for the third time. CytomX jumps 60%+ on masked ADC data in colorectal cancer. Pfiz…
6 months ago
Mar 16, 2026 | Structure Therapeutics Oral GLP-1 Data Rivals Orforglipron; BioMarin Halts Voxzogo Studies
Structure's aleniglipron delivers 16.3% weight loss in Phase2 — challenging Lilly's orforglipron in the oral GLP-1 race. Plus BioMarin's Voxzogo safe…
6 months ago
Mar 15, 2026 | Immutep LAG-3 Phase 3 Failure Crashes Stock 88%; Ultragenyx Gene Therapy Hits OTc
Immutep's LAG-3 drug eftilagimod alfa fails Phase 3 futility analysis in NSCLC—stock drops 88%. Ultragenyx DTX301 gene therapy hits co-primary endpoi…
6 months ago